Bristol Myers Squibb Company $BMY Stake Increased by Tobam

Tobam grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 25.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 81,488 shares of the biopharmaceutical company’s stock after buying an additional 16,626 shares during the period. Bristol Myers Squibb comprises 1.5% of Tobam’s portfolio, making the stock its 27th largest position. Tobam’s holdings in Bristol Myers Squibb were worth $3,772,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of BMY. KBC Group NV raised its holdings in Bristol Myers Squibb by 4.4% during the second quarter. KBC Group NV now owns 4,019,569 shares of the biopharmaceutical company’s stock worth $186,066,000 after purchasing an additional 169,974 shares in the last quarter. Jupiter Asset Management Ltd. raised its stake in Bristol Myers Squibb by 995.5% during the 2nd quarter. Jupiter Asset Management Ltd. now owns 1,338,355 shares of the biopharmaceutical company’s stock valued at $61,952,000 after purchasing an additional 1,216,183 shares during the period. Mitsubishi UFJ Trust & Banking Corp lifted its stake in Bristol Myers Squibb by 3.6% in the 2nd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 2,380,757 shares of the biopharmaceutical company’s stock worth $110,205,000 after acquiring an additional 82,453 shares in the last quarter. Wealth Quarterback LLC boosted its holdings in shares of Bristol Myers Squibb by 42.6% during the second quarter. Wealth Quarterback LLC now owns 25,443 shares of the biopharmaceutical company’s stock worth $1,178,000 after purchasing an additional 7,603 shares during the period. Finally, Advyzon Investment Management LLC grew its holdings in shares of Bristol Myers Squibb by 9.1% during the 2nd quarter. Advyzon Investment Management LLC now owns 7,628 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 639 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a research report on Tuesday, August 5th. Finally, Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Four analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $55.45.

Bristol Myers Squibb Trading Up 3.0%

Shares of BMY stock opened at $48.70 on Wednesday. The firm has a market capitalization of $99.14 billion, a P/E ratio of 19.64, a P/E/G ratio of 2.23 and a beta of 0.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The stock’s fifty day simple moving average is $45.28 and its 200 day simple moving average is $46.68.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the previous year, the business earned $1.80 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were issued a $0.62 dividend. The ex-dividend date of this dividend was Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.1%. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is currently owned by insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.